Corrigendum to "Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats" [Life Sci. 224 (2019) 177-186]
Life Sci. 2022 Jun 1:298:120430.
doi: 10.1016/j.lfs.2022.120430.
Epub 2022 Apr 2.